Knowledge is power. Are you facing a new diagnosis or recurrence of Psoriatic Arthritis? The Spine Community Psoriatic Arthritis Information Center has current, evidence-based information for you. Get the facts about the prevention, treatment, and living with Psoriatic Arthritis. Stay up to date with news, tips, and features designed to keep you informed about the most recent developments and advances. Learn more about Psoriatic Arthritis.
You are not alone—The Spine Community is the leading Social Media Application for individuals seeking information, inspiration, and support for back pain and conditions of the spine. The network offers patients and caregivers a thriving community for support and information. Login or register here.
July 31st, 2017
Obesity is known to have detrimental effects on the musculoskeletal system because of the added strain on joint structures. Another detrimental effect may be the blunting of a therapeutic response to a therapy. It has previously been reported that decreasing weight in psoriatic arthritis results in an improved responses to treatment with tumor necrosis factor […]
May 17th, 2017
Xeljanz (tofacitinib) is currently approved by the U. S. Food and Drug Administration (FDA), for use in the treatment of rheumatoid arthritis. Xeljanz is also being studied in numerous other inflammatory conditions including ankylosing spondylitis, psoriatic arthritis and ulcerative colitis (UC), a form of inflammatory bowel disease. UC is an inflammatory bowel disorder (IBD) as […]
December 20th, 2016
By Tom Macek, M.D. The holidays are a time when everyone is encouraged to be of good cheer. But this joyous time of year is a lot less merry for those suffering from chronic bad backs, migraines, arthritis and other pain-inducing ailments. “Any kind of pain can seriously affect your quality of life,” says Dr. […]
September 22nd, 2016
By David Borenstein MD, Executive Editor, theSpineCommunity.com In January of 2016, the Food and Drug Administration approved Cosentyx® (secukinumab) for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis. Psoriatic spondylitis, an inflammatory spine disease, is a component of PsA responsive to Cosentyx therapy. The availability of Cosentyx allows another option for PsA patients with spine […]
August 23rd, 2016
The Food and Drug Administration’s Arthritis Advisory Committee recommended that Amgen biosimilar (ABP 501) to Humira (adalimumab) be approved for use in the United States. The panel unanimously voted, 26-0, that ABP 501 be recommended for use in the same indications as adalimumab: rheumatoid arthritis (RA), juvenile idiopathic, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, adult Crohn’s disease, […]
August 9th, 2016
A review of the long-term outcomes and safety issues associated with the TNF inhibitor, Humira® (adalimumab) was recently published. Humira works by blocking the inflammatory effects of a protein called tumor necrosis factor alpha (TNF alpha) in rheumatoid arthritis (RA) and other conditions associated with inflammation. The body produces TNF when there is inflammation and […]
June 7th, 2016
By David Borenstein MD, Executive Editor, theSpineCommunity.com What is EULAR? EULAR is an acronym for the European Union League Against Rheumatism. It is the second largest professional rheumatologic organization. The annual meeting for this organization is taking place next week in London, England, where more than a thousand presentations and abstracts will be presented about back […]